Lantheus Holdings, Inc. (NASDAQ:LNTH) Receives Average Rating of “Moderate Buy” from Analysts

Shares of Lantheus Holdings, Inc. (NASDAQ:LNTH) have been given a consensus rating of “Moderate Buy” by the seven brokerages that are presently covering the company, Marketbeat reports. Two analysts have rated the stock with a hold rating and five have assigned a buy rating to the company. The average 12-month target price among brokerages that have updated their coverage on the stock in the last year is $105.50.

A number of research firms recently weighed in on LNTH. Truist Financial set a $63.00 price target on shares of Lantheus and gave the stock a “hold” rating in a research report on Monday, August 11th. JMP Securities lowered their target price on Lantheus from $112.00 to $73.00 and set a “market outperform” rating on the stock in a report on Thursday, August 7th. Mizuho cut their price target on Lantheus from $120.00 to $70.00 and set an “outperform” rating for the company in a report on Thursday, August 7th. B. Riley reduced their price objective on Lantheus from $122.00 to $109.00 and set a “buy” rating on the stock in a research report on Monday, June 23rd. Finally, Wall Street Zen upgraded Lantheus from a “hold” rating to a “buy” rating in a report on Thursday, May 8th.

Lantheus Stock Down 1.1%

Shares of LNTH opened at $54.90 on Wednesday. The stock has a 50 day moving average price of $69.20 and a 200 day moving average price of $83.19. Lantheus has a one year low of $47.25 and a one year high of $118.21. The company has a debt-to-equity ratio of 0.49, a quick ratio of 4.07 and a current ratio of 4.29. The stock has a market capitalization of $3.73 billion, a price-to-earnings ratio of 14.60 and a beta of 0.15.

Lantheus (NASDAQ:LNTH) last announced its earnings results on Wednesday, August 6th. The medical equipment provider reported $1.57 earnings per share (EPS) for the quarter, missing the consensus estimate of $1.65 by ($0.08). Lantheus had a return on equity of 34.06% and a net margin of 17.82%.The business had revenue of $378.05 million for the quarter, compared to analyst estimates of $389.69 million. During the same period last year, the firm earned $1.80 EPS. The company’s revenue for the quarter was down 4.1% compared to the same quarter last year. Equities research analysts forecast that Lantheus will post 6.01 earnings per share for the current fiscal year.

Insider Activity

In other news, insider Farallon Partners L. L. C/Ca sold 3,365,000 shares of the stock in a transaction that occurred on Wednesday, August 20th. The shares were sold at an average price of $56.15, for a total value of $188,944,750.00. Following the completion of the sale, the insider owned 3,477,227 shares of the company’s stock, valued at $195,246,296.05. This represents a 49.18% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. Also, insider Rajiv A. Patel sold 3,365,000 shares of Lantheus stock in a transaction that occurred on Wednesday, August 20th. The shares were sold at an average price of $56.15, for a total transaction of $188,944,750.00. Following the sale, the insider directly owned 3,477,227 shares in the company, valued at approximately $195,246,296.05. The trade was a 49.18% decrease in their position. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 6,812,000 shares of company stock valued at $382,427,380. 2.00% of the stock is owned by company insiders.

Hedge Funds Weigh In On Lantheus

Hedge funds have recently modified their holdings of the business. Janus Henderson Group PLC raised its holdings in Lantheus by 72.7% in the 4th quarter. Janus Henderson Group PLC now owns 6,198,689 shares of the medical equipment provider’s stock valued at $554,583,000 after buying an additional 2,610,118 shares during the period. Farallon Capital Management LLC increased its position in shares of Lantheus by 79.9% during the fourth quarter. Farallon Capital Management LLC now owns 5,316,227 shares of the medical equipment provider’s stock valued at $475,590,000 after acquiring an additional 2,361,000 shares during the last quarter. Westfield Capital Management Co. LP increased its position in shares of Lantheus by 2.2% during the first quarter. Westfield Capital Management Co. LP now owns 1,589,145 shares of the medical equipment provider’s stock valued at $155,101,000 after acquiring an additional 34,052 shares during the last quarter. Reinhart Partners LLC. raised its stake in shares of Lantheus by 16.4% in the 2nd quarter. Reinhart Partners LLC. now owns 1,403,659 shares of the medical equipment provider’s stock valued at $114,905,000 after acquiring an additional 197,719 shares during the period. Finally, Dimensional Fund Advisors LP lifted its holdings in shares of Lantheus by 2.3% in the 1st quarter. Dimensional Fund Advisors LP now owns 1,378,536 shares of the medical equipment provider’s stock worth $134,534,000 after acquiring an additional 31,454 shares during the last quarter. 99.06% of the stock is currently owned by hedge funds and other institutional investors.

About Lantheus

Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer.